Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 27

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 27
---
 at a ratio between 1-for-5 and 1-for-12, with the exact ratio to be determined by the Board (the “Reverse Stock Split) to comply with The Nasdaq Stock Market LLC’s (“Nasdaq”) minimum bid price requirement for continued listing. We filed a Certificate of Amendment to the Certificate of Incorporation, as corrected, on July 30, 2024, and the Reverse Stock Split became effective on August 12, 2024. The Reverse Stock Split reduced the number of our issued and outstanding shares and did not change the par value or authorized shares of our Common Stock. Fractional shares were rounded up to the nearest whole share, and our Common Stock was assigned a new CUSIP number, 83006G203.

Our majority-owned subsidiary, 60P Australia Pty Ltd, an Australian proprietary company limited by shares (“60P Australia”), was formed and registered in Queensland on December 3, 2013, and conducts operations in Australia.

60P Australia previously solely owned a Singaporean subsidiary company, 60P Singapore Pte. Ltd., which dissolved at our election in the second quarter of 2022.

Going Concern

Our independent auditors have issued a report raising substantial doubt of our ability to continue as a going concern. We anticipate that we will require additional capital to continue as a going concern and expand our operations in accordance with our current business plan.

<div align='center'>S-15</div>

Suppliers We have quality and contract manufacturing agreements relating to Arakoda in place with Piramal Enterprises Limited (API, tablets) and PCI Pharma Services (secondary packaging) (“PCI”) and supply/quality/pharmacovigilance agreements in place with Biocelect Pty Ltd, Scandinavian Biopharma, and Knight Therapeutics Inc. (to allow supply of Arakoda/Kodatef to Australia, Europe and Canada/Israel/Latin America and Russia, respectively). As of the date of this prospectus, we have not supplied any of our products to Russia nor do we anticipate supplying any of our products to Russia in the near future. Information Regarding our Capitalization As of February 5, 2025, we had 5,861,054 shares of Common Stock issued and outstanding. Additional information regarding our issued and outstanding securities may be found under “ Description of Securities.” Unless otherwise specifically stated, information throughout this prospectus does not assume the exercise of outstanding options or warrants to purchase shares of our Common Stock. Corporate Information Our principal executive offices are located